Geode Capital Management
INKT icon

Geode Capital Management’s MiNK Therapeutics INKT Stock Holding History

Geode Capital Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Buy
17,345
+3,098
+22% +$34.5K ﹤0.01% 3939
2025
Q4 		$159K Buy
14,247
+1,441
+11% +$18.6K ﹤0.01% 3985
2025
Q3 		$179K Buy
12,806
+1,314
+11% +$21K ﹤0.01% 3962
2025
Q2 		$86K Buy
11,492
+238
+2% +$1.79K ﹤0.01% 4102
2025
Q1 		$97.3K Buy
11,254
+1,643
+17% +$14.6K ﹤0.01% 4039
2024
Q4 		$67K Sell
9,611
-187
-2% -$1.27K ﹤0.01% 4190
2024
Q3 		$73.5K Buy
9,798
+163
+2% +$1.38K ﹤0.01% 4178
2024
Q2 		$91.5K Buy
9,635
+749
+8% +$7.29K ﹤0.01% 4161
2024
Q1 		$80.7K Sell
8,886
-130
-1% -$1.21K ﹤0.01% 4226
2023
Q4 		$96.9K Hold
9,016
– – ﹤0.01% 4196
2023
Q3 		$106K Sell
9,016
-256
-3% -$4.17K ﹤0.01% 4231
2023
Q2 		$195K Buy
9,272
+6,742
+266% +$135K ﹤0.01% 4057
2023
Q1 		$48.6K Hold
2,530
– – ﹤0.01% 4527
2022
Q4 		$65K Buy
2,530
+212
+9% +$4.98K ﹤0.01% 4520
2022
Q3 		$48K Hold
2,318
– – ﹤0.01% 4775
2022
Q2 		$32K Sell
2,318
-1,072
-32% -$20.2K ﹤0.01% 4860
2022
Q1 		$76K Buy
3,390
+1,032
+44% +$31K ﹤0.01% 4728
2021
Q4 		$105K Buy
+2,358
New +$280K ﹤0.01% 4717

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management's INKT Position: Q1 2026 in Review

Geode Capital Management increased its MiNK Therapeutics (INKT) stake by 22% in Q1 2026, buying an estimated $34.5K and bringing the position to 17,345 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Geode Capital Management first reported a position in INKT in Q4 2021 and has held it in 18 quarters since. The position peaked at $195K in Q2 2023. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Geode Capital Management held 17,345 shares of MiNK Therapeutics worth $183K as of Q1 2026.
  • Geode Capital Management bought 3,098 MiNK Therapeutics shares in Q1 2026, an estimated $34.5K.
  • MiNK Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3939 holding.
  • Geode Capital Management first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Geode Capital Management's MiNK Therapeutics position peaked at $195K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.